Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Early Breast Cancer
100%
Response Rate
100%
Estrogen
100%
Luteinizing Hormone
100%
Goserelin
75%
Tumor
50%
Cyclophosphamide
50%
Chemotherapy
50%
Overall Survival
50%
Duration of Response
50%
Fluorouracil
50%
Metastatic Breast Cancer
50%
Estrogen Receptor-positive
50%
Endocrine Therapy
50%
Single-agent Therapy
50%
Postmenopausal Women
50%
Premenopausal Patients
50%
Buserelin
50%
Prostate Cancer
25%
Effective Means
25%
Breast Cancer
25%
Disease-free Survival
25%
Metastatic Disease
25%
Malignancy
25%
Breast Cancer Patients
25%
Median Overall Survival
25%
Adjuvant Therapy
25%
Randomized Trial
25%
Ongoing Trials
25%
Doxorubicin
25%
Combination Therapy
25%
Progression-free Survival
25%
Adriamycin
25%
Time to Progression
25%
Cellular Level
25%
Meta-analysis
25%
Recurrence Risk
25%
Methotrexate
25%
Agonist Treatment
25%
Postmenopausal Breast Cancer
25%
Aromatase Inhibitors
25%
Randomized Prospective Study
25%
Survival Response
25%
Estrogen Deprivation
25%
Ovarian Function
25%
Estrogen Production
25%
In Vivo Interaction
25%
Interacting Agents
25%
Nursing and Health Professions
Breast Cancer
100%
Tamoxifen
100%
Estrogen
100%
Gonadorelin Agonist
50%
Overall Survival
37%
Goserelin
37%
Cyclophosphamide
25%
Hormonal Therapy
25%
Chemotherapy
25%
Fluorouracil
25%
Doxil
25%
Estrogen Receptor
25%
Metastatic Breast Cancer
25%
Efficacy
25%
Buserelin
25%
Combination Therapy
12%
Diseases
12%
Recurrent Disease
12%
Prostate Cancer
12%
Adjuvant Therapy
12%
Aromatase Inhibitor
12%
Methotrexate
12%
Progression Free Survival
12%
Disease Free Survival
12%
Meta Analysis
12%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Tamoxifen
100%
Estrogen
100%
Gonadorelin Agonist
50%
Overall Survival
37%
Goserelin
37%
Cyclophosphamide
25%
Doxorubicin
25%
Fluorouracil
25%
Estrogen Receptor
25%
Metastatic Breast Cancer
25%
Endocrine Therapy
25%
Buserelin
25%
Chemotherapy Regimen
25%
Diseases
12%
Disease Free Survival
12%
Prospective Study
12%
Prostate Cancer
12%
Recurrent Disease
12%
Combination Therapy
12%
Progression Free Survival
12%
Methotrexate
12%
Aromatase Inhibitor
12%
Neuroscience
Tamoxifen
100%
Estrogen
100%
Gonadotropin-Releasing Hormone Agonist
50%
Goserelin
37%
Cyclophosphamide
25%
Doxorubicin
25%
Estrogen Receptor
25%
Chemotherapy
25%
Hormone Therapy
25%
Fluorouracil
25%
Buserelin
25%
In Vivo
12%
Prostate
12%
Adjuvant Therapy
12%
Meta-Analysis
12%
Methotrexate
12%
Aromatase Inhibitor
12%